5-Methoxy 2-aminoindane - Clearmind Medicine
Alternative Names: 5-MeO-AI - Clearmind Medicine; CMND-100; MEAI - Clearmind MedicineLatest Information Update: 22 Dec 2025
At a glance
- Originator Clearmind Medicine
- Developer Clearmind Medicine; SciSparc
- Class Amines; Antipsychotics; Drug withdrawal therapies; Ethers; Indans; Obesity therapies
- Mechanism of Action 5-HT1A serotonin receptor modulators; Serotonin 5-HT2A receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Alcoholism
- Preclinical Cocaine-related disorders; Metabolic syndrome; Obesity
Most Recent Events
- 16 Dec 2025 Efficacy data from a phase I/IIa trial in Alcoholism released by Clearmind Medicine
- 24 Nov 2025 Clearmind Medicine’s Data and Safety Monitoring Board unanimously approved the continuation of the phase I/IIa clinical trial for CMND 100 following a positive interim safety review
- 18 Nov 2025 Top-line efficacy data from a phase I/IIa trial in Alcoholism released by Clearmind Medicine